BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079
This study is recruiting at 16 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
- NSCLC
- PDAC - Pancreatic Ductal Adenocarcinoma
- CRC (Colorectal Cancer)
- Metastatic Non-Small Lung Cell Cancer
- Metastatic Colorectal Cancer (CRC)
- KRAS G12A
- KRAS G12C
- KRAS G12D
- KRAS G12S
- KRAS G12V
- Metastatic Pancreatic Ductal Adenocarcinoma
- Advanced Lung Carcinoma
- Solid Tumor, Adult
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Last updated on ClinicalTrials.gov
- June 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles, CA
- University of California Davis · Sacramento, CA
- University of California San Diego Moores Cancer Center · San Diego, CA
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
Connecticut · 1
- Yale University · New Haven, CT
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Illinois · 1
- OSF Healthcare Cancer Institute · Peoria, IL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
New York · 2
- Columbia University Irving Medical Center · New York, NY
- NYU Langone Health · New York, NY
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Texas · 3
- Sarah Cannon Research Institute at Mary Crowley · Dallas, TX
- The University of Texas MD Anderson Cancer Center · Houston, TX
- NEXT Oncology · San Antonio, TX
Utah · 1
- Huntsman Cancer Institute · Salt Lake City, UT
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.